Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Quarterly Earnings Results

Eupraxia Pharmaceuticals (NASDAQ:EPRX) released its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, Zacks reports.

Eupraxia Pharmaceuticals Stock Down 2.7 %

Shares of EPRX traded down $0.11 during midday trading on Thursday, hitting $3.91. The company had a trading volume of 5,147 shares, compared to its average volume of 16,544. The company’s 50 day moving average price is $3.46 and its 200 day moving average price is $3.09. The stock has a market cap of $139.38 million and a price-to-earnings ratio of -5.43. Eupraxia Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $4.48.

Analyst Ratings Changes

Separately, Craig Hallum assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They set a “buy” rating and a $12.00 price target on the stock.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.